Description

The SCAMP2 Knockout U-251MG Cell Line is a CRISPR/Cas9-edited human glioblastoma cell model featuring targeted disruption of the SCAMP2 gene. This cell line provides a stable loss-of-function system for investigating secretory carrier membrane protein 2 function in a central nervous system cancer background. The knockout was generated using CRISPR/Cas9 genome editing to introduce targeted gene disruption in the U-251MG host cell line, creating a reliable tool for studying post-Golgi trafficking, exocytic pathways, and receptor recycling. As a knockout cell line, it enables constitutive SCAMP2 depletion, eliminating dynamic compensation mechanisms often observed with transient silencing approaches and allowing long-term functional studies under defined culture conditions.

The U-251MG host cell line is derived from a human glioblastoma multiforme tumor and exhibits an adherent, epithelial-like morphology. This line serves as a widely used model for glioblastoma, the most aggressive primary brain cancer, and retains key oncogenic signaling networks relevant to glioma biology. U-251MG cells are characterized by dysregulated receptor tyrosine kinase signaling, invasive behavior, and altered intracellular trafficking pathways that contribute to therapeutic resistance. The adherent growth properties facilitate imaging-based assays and biochemical analyses, making this background particularly suitable for detailed mechanistic studies of membrane dynamics.

SCAMP2 encodes a secretory carrier membrane protein that operates at the interface of post-Golgi vesicle formation and SNARE-mediated exocytosis. SCAMP2 interacts with syntaxin-4, SNAP-25, and the AP-2 clathrin adaptor complex, thereby regulating the docking and fusion of secretory vesicles with the plasma membrane. It is activated downstream of insulin and epidermal growth factor (EGF) signaling, and its function is modulated by phosphorylation via protein kinase C (PKC) and casein kinase II (CK2). SCAMP2 mediates epidermal growth factor receptor (EGFR) recycling and insulin-stimulated GLUT4 translocation through direct SNARE complex assembly. Disruption of SCAMP2 therefore impairs these critical receptor and transporter trafficking events, leading to altered surface receptor expression and downstream pathway output.

In the glioblastoma context, loss of SCAMP2 is predicted to perturb EGFR recycling and exocytic release of growth factors, potentially attenuating autocrine and paracrine signaling loops that drive tumor proliferation and invasion. The U-251MG line harbors genetic alterations that activate receptor tyrosine kinase pathways, making it highly dependent on efficient endosomal sorting and recycling. By uncoupling SCAMP2 from SNARE fusion machinery and clathrin-mediated internalization, this knockout model reveals how secretory pathway dysregulation intersects with oncogenic signaling, offering insights into synthetic vulnerabilities. Moreover, the model allows dissection of how glioblastoma cells modulate their secretome to influence the tumor microenvironment.

The SCAMP2 Knockout U-251MG Cell Line supports a broad range of research applications, including quantitative analysis of EGFR recycling kinetics via pulse-chase assays, examination of SNARE complex integrity by co-immunoprecipitation, and functional assessment of regulated exocytosis using ELISA-based secretion measurements. It is instrumental for studying the role of SCAMP2 in glioblastoma cell migration and invasion, evaluating chemotherapeutic drug resistance linked to altered surface receptor residency, and profiling secreted factors under varying experimental conditions. Standard validation techniques include western blotting, immunofluorescence, and flow cytometry. For detailed inquiries about model characterization and application protocols, please contact Ascent Research.